-
1دورية أكاديمية
المؤلفون: Singh, Lakshmi G.1,2 (AUTHOR), Ntelis, Spyridon1,3 (AUTHOR), Siddiqui, Tariq1,4 (AUTHOR), Seliger, Stephen L.5,6 (AUTHOR), Sorkin, John D.7,8 (AUTHOR), Spanakis, Elias K.1,4 (AUTHOR) ispanakis@som.umaryland.edu
المصدر: Diabetes Care. Jun2024, Vol. 47 Issue 6, p933-940. 8p.
مصطلحات موضوعية: *CANAGLIFLOZIN, *SODIUM-glucose cotransporter 2 inhibitors, *HOSPITAL patients, *PEOPLE with diabetes, *COHORT analysis, *ACUTE kidney failure
-
2دورية أكاديمية
المؤلفون: Weissman, Yaara Leibovici1,2 (AUTHOR), Calvarysky, Bronislava3,4 (AUTHOR), Shochat, Tzippy5 (AUTHOR), Korotkov, Zoya6 (AUTHOR), Grossman, Alon2,6 (AUTHOR), Leibovici, Leonard2,7 (AUTHOR), Turjeman, Adi2,7 (AUTHOR) aditur88@gmail.com
المصدر: Diabetes Care. Apr2024, Vol. 47 Issue 4, p692-697. 6p.
مصطلحات موضوعية: *ISRAELIS, *SODIUM-glucose cotransporter 2 inhibitors, *ACUTE kidney failure, *URINARY tract infections, *COHORT analysis
مصطلحات جغرافية: ISRAEL
-
3دورية أكاديمية
المؤلفون: Tobe, Sheldon W.1,2 sheldon.tobe@sunnybrook.ca, Mavrakanas, Thomas A.3, Bajaj, Harpreet S.4, Levin, Adeera5, Tangri, Navdeep6,7, Slee, April8, Neuen, Brendon L.9,10, Perkovic, Vlado9,10,11, Mahaffey, Kenneth W.12, Rapattoni, Wally13, Ang, Fernando G.13
المصدر: Diabetes Care. Mar2024, Vol. 47 Issue 3, p501-507. 7p.
مصطلحات موضوعية: *TYPE 2 diabetes, *SODIUM-glucose cotransporter 2 inhibitors, *CANAGLIFLOZIN, *DIABETIC nephropathies, *KIDNEY failure
-
4دورية أكاديمية
المؤلفون: Naaman, Sandra C.1, Bakris, George L.1 gbakris@uchicago.edu
المصدر: Diabetes Care. Sep2023, Vol. 46 Issue 9, p1574-1586. 13p.
مصطلحات موضوعية: *SODIUM-glucose cotransporter 2 inhibitors, *GLUCAGON-like peptide 1, *MINERALOCORTICOID receptors, *PEPTIDE receptors, *HEART failure, *DIABETIC nephropathies, *DISEASE progression
-
5دورية أكاديمية
المؤلفون: Daniele, Giuseppe, Tura, Andrea, Brocchi, Alex, Saba, Alessandro, Campi, Beatrice, Sancho-Bornez, Veronica, Dardano, Angela, Del Prato, Stefano
المصدر: Diabetes Care; Jul2024, Vol. 47 Issue 7, p1131-1139, 9p
مصطلحات موضوعية: DAPAGLIFLOZIN, TYPE 2 diabetes, METABOLIC clearance rate, SODIUM-glucose cotransporter 2 inhibitors, GLUCAGON-like peptide 1, CD26 antigen
-
6دورية أكاديمية
المؤلفون: Sattar, Naveed, Presslie, Calum, Rutter, Martin K., McGuire, Darren K.
المصدر: Diabetes Care; Apr2024, Vol. 47 Issue 4, p531-543, 13p
مصطلحات موضوعية: HEART failure, TYPE 2 diabetes, DISEASE risk factors, SODIUM-glucose cotransporter 2 inhibitors, OBESITY, CARDIOVASCULAR diseases risk factors
-
7دورية أكاديمية
المؤلفون: Karagiannis, Thomas, Tsapas, Apostolos, Bekiari, Eleni, Toulis, Konstantinos A., Nauck, Michael A.
المصدر: Diabetes Care; Feb2024, Vol. 47 Issue 2, p184-192, 9p
مصطلحات موضوعية: MAJOR adverse cardiovascular events, TYPE 2 diabetes, SODIUM-glucose cotransporter 2 inhibitors, GLUCAGON-like peptide-1 agonists, GLUCAGON-like peptide 1
-
8دورية أكاديمية
المؤلفون: Yates, Thomas ty20@le.ac.uk, Sargeant, Jack A., King, James A., Henson, Joe, Edwardson, Charlotte L., Redman, Emma, Gulsin, Gaurav S., Brady, Emer M., Ahmad, Ehtasham, Stensel, David J., Webb, David R., McCann, Gerry P., Khunti, Kamlesh, Davies, Melanie J.
المصدر: Diabetes Care. Nov2022, Vol. 45 Issue 11, p2749-2752. 4p.
مصطلحات موضوعية: *PHYSICAL activity, *SODIUM-glucose cotransporter 2 inhibitors, *GLUCAGON-like peptide 1, *CD26 antigen, *PEPTIDE receptors
-
9دورية أكاديمية
المؤلفون: Daya, Natalie R.1 (AUTHOR), Fang, Michael1 (AUTHOR), Mathew, Mahesh2 (AUTHOR), Shin, Jung-Im1 (AUTHOR), Pankow, James2 (AUTHOR), Lutsey, Pamela L.2 (AUTHOR), Valint, Arielle3 (AUTHOR), Echouffo-Tcheugui, Justin B.1,4 (AUTHOR), Selvin, Elizabeth1 (AUTHOR) eselvin@jhu.edu
المصدر: Diabetes Care. Feb2024, Vol. 47 Issue 2, pe9-e10. 2p.
مصطلحات موضوعية: *SODIUM-glucose cotransporter 2 inhibitors, *SODIUM-glucose cotransporters, *BIOMARKERS
-
10دورية أكاديمية
المؤلفون: Hawley, Chelsea E., Lauffenburger, Julie C., Paik, Julie M., Wexler, Deborah J., Kim, Seoyoung C., Patorno, Elisabetta epatorno@bwh.harvard.edu
المصدر: Diabetes Care. 2022, Vol. 45 Issue 3, p604-613. 10p.
مصطلحات موضوعية: *SODIUM-glucose cotransporter 2 inhibitors, *MEDICARE beneficiaries, *SODIUM-glucose cotransporters, *TYPE 2 diabetes, *OLDER patients, *PATIENT compliance